Clinical Characterization of FGFR-Altered Pediatric Low-Grade Gliomas.

doi:10.1002/1545-5017.70438

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical Characterization of FGFR-Altered Pediatric Low-Grade Gliomas.

Pediatric blood & cancer - 1 Sept 2026

Posorske Benjamin, Borden Elizabeth S, Gallus Shea, Gilani Ahmed, Tiwari Nishant, Vaughn Jennifer, Neuberger Ilana, Keller Lisa, Sivakumaran Theru A, Azab Bilal, Temkit M'hamed, Dorris Kathleen, Goldman Stewart, Hoffman Lindsey M, Mangum Ross

Abstract excerpt

Pediatric low-grade gliomas (pLGG) are the predominant childhood central nervous system tumors. While BRAF alterations are known to drive the majority of pLGGs, a subgroup contains activating mutations or fusions involving FGFR1/2/3. FGFR is a receptor tyrosine kinase that plays a crucial role in cell growth, differentiation, and survival through interactions with fibroblast growth factors. Furthermore, FGFR has...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Child, Preschool

Share to FGFR1 gene

Share to Glioma

Share to Mutation

Share to Receptor, Fibroblast Growth Factor, Type 1

Share to Receptors, Fibroblast Growth Factor

Source

Open in PubMed

Identifiers

PMID: 42527824
DOI: 10.1002/1545-5017.70438

Genes

BRAF
FGFR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.